Sorafenib Tosylate Patent Expiration
Sorafenib Tosylate is Used for treating advanced renal cell carcinoma, carcinoma of the thyroid, and unresectable hepatocellular carcinoma. It was first introduced by Bayer Healthcare Pharmaceuticals Inc
Sorafenib Tosylate Patents
Given below is the list of patents protecting Sorafenib Tosylate, along with the drug name that holds that patent and the company name owning that drug.
| Drug Used in | Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Drug Owner |
|---|---|---|---|---|
| Nexavar | US9737488 | Pharmaceutical composition for the treatment of cancer | Sep 10, 2028 | Bayer Hlthcare |
| Nexavar | US8877933 | Thermodynamically stable form of a tosylate salt | Dec 24, 2027 | Bayer Hlthcare |
| Nexavar | US8618141 | Aryl ureas with angiogenesis inhibiting activity |
Feb 11, 2023
(Expired) | Bayer Hlthcare |
| Nexavar | US7235576 | Omega-carboxyaryl substituted diphenyl ureas as raf kinase inhibitors |
Jan 12, 2020
(Expired) | Bayer Hlthcare |
| Nexavar | US7351834 | ω-Carboxyaryl substituted diphenyl ureas as raf kinase inhibitors |
Jan 12, 2020
(Expired) | Bayer Hlthcare |
| Nexavar | US7897623 | ω-carboxyl aryl substituted diphenyl ureas as p38 kinase inhibitors |
Jan 12, 2020
(Expired) | Bayer Hlthcare |
| Nexavar | US8124630 | ω-carboxyaryl substituted diphenyl ureas as raf kinase inhibitors |
Jan 12, 2020
(Expired) | Bayer Hlthcare |
| Nexavar | US8841330 | Omega-carboxyaryl substituted diphenyl ureas as raf kinase inhibitors |
Jan 12, 2020
(Expired) | Bayer Hlthcare |
Sorafenib Tosylate's Family Patents
Explore Our Curated Drug Screens
Clinical Trials
Recent Clinical Trials on Sorafenib Tosylate:
Sometimes companies keep conducting clinical trials even after the drug's approval to discover new formulations, methods of use, or new treatment indications, so they could file for additional patents or receive regulatory exclusivity extensions, such as pediatric exclusivity, potentially delaying generic competition. Based on these recent clinical trials, generic companies need to consider the potential for new intellectual property or regulatory hurdles. These strategic moves by the drug owner might delay generic substitution or lead to additional sales of the brand drug, even after patent expiry.
| Title | Lead Sponsor | Collaborators | Status | Phases |
|---|---|---|---|---|
 | ||||
| Sorafenib in Treating Patients With Angiosarcoma That is Locally Advanced, Metastatic, or Unable to Be Removed by Surgery | Centre Oscar Lambret | NA |
COMPLETED
(Sep 1, 2026)
| PHASE2 |
| Sunitinib Malate or Sorafenib Tosylate in Treating Patients With Kidney Cancer That Was Removed By Surgery | National Cancer Institute (NCI) | NA |
COMPLETED
(May 1, 2026)
| PHASE3 |
| Sorafenib Tosylate in Treating Patients With Desmoid Tumors or Aggressive Fibromatosis | National Cancer Institute (NCI) | NA |
COMPLETED
(May 1, 2026)
| PHASE3 |